Lenvatinib/Pembrolizumab/Chemo Induces Inferior OS vs Pembrolizumab/Chemo in Previously Untreated NSCLC

Lenvatinib plus pembrolizumab, pemetrexed, and carboplatin or cisplatin did not improve treatment outcomes compared with placebo plus pembrolizumab, pemetrexed, and carboplatin or cisplatin when given as first-line therapy in patients with stage IV nonsquamous non–small cell lung cancer.

Related Keywords

Connecticut ,United States ,New Haven ,Lenvatinib Lenvima ,Roys Herbst ,Yale Cancer Center ,Thoracic Cancers At Yale Cancer Center ,Yale School Of Medicine ,Oncology Annual Congress ,Oncology Annual ,Medical Oncology ,Thoracic Cancers ,Smilow Cancer ,Yale School ,East Asia ,Lenvatinib Plus Pembrolizumab ,Pemetrexed ,Nd Carboplatin Or Cisplatin ,Placebo Plus Pembrolizumab ,Patients With Stage Iv Nonsquamous Non Small Cell Lung Cancer ,Nct03829319 ,Leap 006 Trial ,D ,Phd ,Smilow Cancer Hospital ,